Improvement in progression-free survival and safety demonstrated with the addition of vistusertib to anastrozole vs anastrozole alone in patients with hormone receptor−positive recurrent or metastatic endometrial cancer.
Paxalisib has been granted orphan drug designation by the FDA for the treatment of patients with atypical rhabdoid or teratoid tumors in rare and aggressive childhood brain cancer.
The ASCO’s expert panel released updated recommendations of pembrolizumab in combination with neoadjuvant chemotherapy for patients with stage II or stage III early triple-negative breast cancer
Data regarding the triplet combination of nivolumab, ipilimumab, and cabozantinib show clinical activity across multiple tumor types, giving a preview of future outcomes in patients with untreated, advanced renal cell carcinoma.
Pediatric low-grade glioma is the most common type of brain tumor found in children with cancer, and there are currently no approved treatments or standard of care to combat it.
A tumor genomic profiling program has shown feasibility and clinical impact for pediatric patients who are high-risk de novo and relapsed/refractory.
Quizartinib with standard induction and consolidation chemotherapy followed by continued quizartinib monotherapy treatment led to significant improvement in overall survival in patients with newly diagnosed FLT3-ITD–positive acute myeloid leukemia.
Selinexor has demonstrated improvement in progression-free survival over placebo in patients with advanced or recurrent endometrial cancer.
Adjuvant pembrolizumab led to improved disease-free survival versus placebo in patients with fully resected non–small cell lung cancer, according to second interim results from the PEARLS/KEYNOTE-091 trial.
Adjuvant pembrolizumab improved distant metastasis-free survival and longer follow up for recurrence-free survival in patients with resected stage IIB or stage IIC melanoma, according to data discussed at the 2022 ASCO Annual Meeting.
RV001 did not show superiority to placebo in terms of preventing progression of disease in patient with prostate cancer.
A new report from ASCO and the ACCC provides recommendations on how to better represent a wider range of patients from different backgrounds, preferences, and identities within the clinical trial setting.
Patients with tumors harboring PIK3CA mutations reported a better objective response rate when given copanlisib compared to those with the null hypothesis.
The phase 2 MOUNTAINEER trial of tucatinib plus trastazumab in patients with previously treated HER2-positive metastatic colorectal cancer demonstrates positive results.
Orphan drug designation has been granted by the FDA to XMT-2056 for the treatment of patients with gastric cancers.
With results offering promising efficacy data and a manageable safety profile, unecritinib can be regarded as a new first-line treatment option.
Based on responses, patient knowledge of cancer-associated thrombosis is subpar and requires clinicians to better provide patients with the proper information regarding cancer-associated thrombosis warning signs, symptoms, and preventions.
In preclinical study, researchers have identifies anti-TIGIT therapy as a potentially effective strategy for improving remission rates in patients with non-Hodgkin lymphoma after chimeric antigen receptor T-cell therapy.
Interim results of the ADVANCE II study of DCP-001 revealed durable measurable residual disease responses in patients with acute myeloid leukemia.
In relapse/refractory follicular lymphoma, promising results have been observed with PI3K inhibitors and are encouraging because of the less than optimal outcome associated with Bruton's tyrosine kinase inhibitors.
Patients with metastatic castration-resistant prostate cancer treated with darolutamide for more than 4 years tolerated well the adverse effects of the drug.
Findings from a phase 1 study of CART-ddBCMA cells exemplify their safety and ability to induce durable responses in patients with relapsed or refractory multiple myeloma.
The demonstration of clinical benefit of oleclumab or monalizumab added to durvalumab vs durvalumab alone in the COAST study support further evaluation of these combinations in the larger study.
The first participants have been enrolled in the CASCADE-LUNG study, a prospective, multicenter trial.
Less medically complex patients with cancer are more likely to use telemedicine services, according to new study results.
Results of the SEAL study revealed a 30% progression-free survival improvement in patients with advanced, metastatic dedifferentiated liposarcoma who underwent selinexor therapy as well as other efficacy and safety benefits.
Florida Cancer Specialists & Research Institute sites and site worldwide are now recruiting patients for the PROPHETIC study.
Treatment with avasopasem manganese reduced the incidence of radiation-induced, severe esophagitis in patients with lung cancer undergoing chemoradiotherapy, according to AESEOP trial findings.
A lower overall risk of neurologic adverse events was seen in patients who received immune checkpoint treatment versus chemotherapy control groups.